Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENO Lime is an **effervescent antacid powder** formulation marketed for fast and effective relief from acidity, heartburn, indigestion, bloating, and related symptoms. Its primary mechanism is rapid **neutralization of excess gastric acid**, acting within seconds to alleviate discomfort. The active ingredients are **sodium bicarbonate, citric acid, and sodium carbonate**, which react in water to form carbon dioxide (fizz) and neutralize stomach acid. The formulation is flavored with lime for palatability. ENO Lime is used mainly for acute, symptomatic relief of excess stomach acid and mild digestive upsets. It does not treat underlying causes of chronic gastrointestinal disorders. ENO as a brand was originally developed in the UK and is currently produced and marketed globally, especially throughout Asia and India, by Haleon (formerly GlaxoSmithKline Consumer Healthcare)[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ENO Lime.